Mettler-Toledo International Inc. — Q3 2018 Form 10-Q
Business context and period. Global supplier of precision instruments and related services, including laboratory, industrial, food retailing, packaging and process analytics products. This unaudited filing covers the quarter and nine months ended September 30, 2018; financial amounts below are in millions of U.S. dollars unless stated otherwise.
Financial performance
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Net sales | $734.8 | $698.8 | $2,117.7 | $1,947.0 |
| Gross profit | $419.3 | $401.0 | $1,206.8 | $1,120.0 |
| Gross margin | 57.1% | 57.4% | 57.0% | 57.5% |
| Earnings before taxes | $160.4 | $139.6 | $421.4 | $380.3 |
| Net earnings | $126.7 | $105.0 | $331.4 | $299.0 |
| Diluted EPS | $4.93 | $3.99 | $12.81 | $11.31 |
- Sales rose 5% in U.S. dollars and 7% in local currencies in Q3; nine-month sales increased 9% and 6%, respectively. Biotix contributed about 1% to local-currency sales growth in both periods.
- Net earnings increased about 21% in Q3 and 11% year to date. Diluted EPS increased about 24% and 13%, respectively, with lower weighted-average diluted share counts supporting per-share growth.
- Gross margin declined 0.3 percentage points in Q3 and 0.5 points year to date. Management cited new-facility and product-introduction costs, Biotix, unfavorable mix and tariffs, partly offset by pricing. Q3 SG&A fell to 27.6% of sales from 29.6%; year-to-date it was 28.9% versus 30.2%.
Cash flow, debt and liquidity
- Nine-month operating cash flow was $366.4 million, versus $351.2 million. Capital expenditures were $96.7 million, versus $85.8 million; operating cash flow less capital expenditures was approximately $269.8 million.
- Cash and cash equivalents were $137.4 million at September 30, 2018. Total debt was $1,044.6 million, including $55.8 million current; long-term debt was $988.9 million. The resulting debt less cash was approximately $907.2 million.
- The amended $1.1 billion revolving credit facility had $601 million of availability. The company reported compliance with its covenants. Management said operating cash flow and available facilities should cover anticipated working capital and capital spending for the foreseeable future.
- Current assets were $971.5 million and current liabilities $697.5 million. The filing reports $39.6 million of short-term loans issued by two non-U.S. pension plans to a subsidiary; proceeds repaid credit-facility borrowings.
- The company repurchased $356.2 million of shares during the first nine months. Remaining program authorization was $227.2 million at quarter-end; on November 8, the Board authorized an additional $2.0 billion.
Changes, outlook and risks
- Performance was uneven by product category: laboratory sales grew 11% in local currency in Q3 and 10% year to date; industrial sales grew 1% and 1%; food retailing grew 14% and 6%. China and Asia/Rest of World were notable growth areas; management said overall market conditions were generally favorable but remained cautious.
- U.S. tariffs on certain China-origin products were estimated to add approximately $25 million in annualized cost at a 25% tariff rate. The company was evaluating and implementing mitigation actions.
- Foreign exchange is a material exposure. Management estimated that a 1% Swiss franc strengthening against the euro would reduce annual pretax earnings by $1.6–$1.8 million; a 1% renminbi weakening against the U.S. dollar would reduce them by $1.2–$1.4 million. A 10% weakening of the U.S. dollar against debt currencies could increase reported debt by about $28 million.
- Restructuring charges were $2.2 million in Q3 and $14.0 million year to date, primarily related to facility consolidation. The company expects approximately $20 million of net investment in new or expanded manufacturing facilities over the next two years. No specific full-year sales or EPS guidance is stated in the supplied filing text.
- The company was completing its accounting for the 2017 U.S. tax law during Q4 2018 and estimated any resulting adjustments would not be material. The 2017 Transition Tax provision was $72 million; $4.2 million was paid in April 2018, with much of the balance payable over up to eight years.
- Management did not expect pending ordinary-course legal and environmental proceedings, individually or collectively, to materially affect financial condition, results or cash flows. The filing reported no material risk-factor changes from the 2017 Form 10-K and no material change in market-risk disclosures.
Key investor verification points
- Confirm whether tariff mitigation and product mix improve gross margin, and track the actual tariff cost against management’s estimated annualized $25 million.
- Assess whether strong laboratory and China growth persists, given management’s cautions about economic uncertainty and international trade disputes.
- Review debt, covenant headroom and funding plans alongside the expanded $2.0 billion repurchase authorization and planned facility investments.
- Monitor currency impacts, restructuring spending and final tax-law accounting adjustments; the filing notes reported results may not indicate full-year performance.